[go: up one dir, main page]

FI20000720A7 - Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi - Google Patents

Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi Download PDF

Info

Publication number
FI20000720A7
FI20000720A7 FI20000720A FI20000720A FI20000720A7 FI 20000720 A7 FI20000720 A7 FI 20000720A7 FI 20000720 A FI20000720 A FI 20000720A FI 20000720 A FI20000720 A FI 20000720A FI 20000720 A7 FI20000720 A7 FI 20000720A7
Authority
FI
Finland
Prior art keywords
parkinson
disease
extended
treatment
release tablet
Prior art date
Application number
FI20000720A
Other languages
English (en)
Swedish (sv)
Other versions
FI20000720L (fi
Inventor
Tzu-Chi Robert Ju
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI20000720A7 publication Critical patent/FI20000720A7/fi
Publication of FI20000720L publication Critical patent/FI20000720L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI20000720A 1997-09-30 2000-03-29 Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi FI20000720L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (2)

Publication Number Publication Date
FI20000720A7 true FI20000720A7 (fi) 2000-03-29
FI20000720L FI20000720L (fi) 2000-03-29

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20000720A FI20000720L (fi) 1997-09-30 2000-03-29 Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi

Country Status (22)

Country Link
US (2) US6197339B1 (fi)
EP (1) EP1017391B1 (fi)
JP (1) JP2001517701A (fi)
KR (1) KR100516095B1 (fi)
CN (1) CN1195518C (fi)
AT (1) ATE297208T1 (fi)
AU (1) AU742941B2 (fi)
BR (1) BR9812687A (fi)
CA (1) CA2301869A1 (fi)
DE (1) DE69830503T2 (fi)
DK (1) DK1017391T3 (fi)
ES (1) ES2242296T3 (fi)
FI (1) FI20000720L (fi)
HU (1) HUP0004586A2 (fi)
NO (1) NO320303B1 (fi)
NZ (1) NZ504221A (fi)
PL (1) PL191125B1 (fi)
PT (1) PT1017391E (fi)
RU (1) RU2205007C2 (fi)
SI (1) SI1017391T1 (fi)
SK (1) SK3612000A3 (fi)
WO (1) WO1999016442A2 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355802B1 (en) 1999-02-05 2002-03-12 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2(1h)-one
EE05022B1 (et) 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
AU2003277296A1 (en) * 2002-10-04 2004-05-04 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
EP1546120A4 (en) * 2002-10-04 2006-11-22 Pharmacia Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1569649A2 (en) * 2002-10-25 2005-09-07 Pharmacia & Upjohn Company LLC Use of heterocyclic amine-type compounds as neuroprotective agents
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1592453A1 (en) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
RS52057B2 (sr) * 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013041462A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
AU2021464980A1 (en) * 2021-09-17 2024-05-02 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) * 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
HUP0004586A2 (hu) 2001-06-28
AU9296498A (en) 1999-04-23
WO1999016442A3 (en) 1999-06-17
RU2205007C2 (ru) 2003-05-27
CA2301869A1 (en) 1999-04-08
DK1017391T3 (da) 2005-08-22
SI1017391T1 (sl) 2005-12-31
DE69830503D1 (de) 2005-07-14
DE69830503T2 (de) 2006-03-16
PT1017391E (pt) 2005-09-30
BR9812687A (pt) 2000-08-22
ES2242296T3 (es) 2005-11-01
AU742941B2 (en) 2002-01-17
WO1999016442A2 (en) 1999-04-08
FI20000720L (fi) 2000-03-29
ATE297208T1 (de) 2005-06-15
US6197339B1 (en) 2001-03-06
NZ504221A (en) 2004-11-26
CN1268890A (zh) 2000-10-04
KR20010030776A (ko) 2001-04-16
NO20001624L (no) 2000-03-29
HK1030163A1 (en) 2001-04-27
JP2001517701A (ja) 2001-10-09
EP1017391B1 (en) 2005-06-08
NO20001624D0 (no) 2000-03-29
KR100516095B1 (ko) 2005-09-23
EP1017391A2 (en) 2000-07-12
PL191125B1 (pl) 2006-03-31
PL339946A1 (en) 2001-01-15
CN1195518C (zh) 2005-04-06
NO320303B1 (no) 2005-11-21
SK3612000A3 (en) 2000-09-12
US20010053386A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
EE9900469A (et) Sulfoonamiidid endoteliini vahendatud haiguste raviks
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP0331620A3 (en) Agent for the treatment of parkinson's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
IL119417A0 (en) Drug for Parkinson's disease
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
ZA963935B (en) The use of glyceryl triacetate for treatment of onychomycoses
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
NO982562D0 (no) Sammensetning for behandling av smerte
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
ZA986324B (en) Composition for the treatment of immunodeficiency disease
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states